In Vitro Diagnostics Market to Witness Swift Growth
|
By LabMedica International staff writers Posted on 26 May 2016 |
The global in vitro diagnostics (IVD) market is expected to expand rapidly owing to an aging population, chronic lifestyle related diseases, and increased usage of personalized medicine and point-of-care (POC) testing. These are the latest findings of Grand View Research (San Francisco, CA, USA), a market research and consulting company.
Applications of IVD include oncology, cancer, nephrology, cardiology, drug testing, autoimmune diseases, diabetes and infectious diseases, with tests being used by a wide range of customers, including academic institutes, hospitals, and laboratories. Home testing is another application resulting from innovations and advancement in various IVD technologies, further enhancing the increasing role of POC disease diagnostics. This, along with the need for identification of malaria and filiarsis pathogens, are some of the key drivers of IVD market.
Increased consumer awareness of serious health issues such as diabetes, cancer, and sexually transmitted diseases are also rapidly altering the healthcare environment, creating a need for point-of-care (POC) recognition and detection of communicable diseases such as respiratory infections, respiratory syncytial virus (RSV), influenza, and pneumonia. Of particular interest is the tissue IVD market, which is expected to rise owing to the increasing incidents of lung and bronchus cancer, melanoma, and prostate breast cancer diagnosis.
Product-wise, the in IVD market is segmented into instruments, services, data management systems, reagents, and kits that are intended to diagnose, cure, prevent, or treat a particular disease. Different techniques are involved, including molecular diagnostics, blood tests, clinical chemistry, microbiological diagnostic techniques, and flow cytometry. The most commonly used technologies include electrolyte and metabolic panels; lipid and renal profiles; hematology, coagulation, and hemostasis microarrays; and radioimmunoassay and specialty chemicals, among others.
In 2014, North America was the largest regional segment, with about 43% market share owing to established distribution channels, extraordinary diagnostics in cancer screening, and prevalent disorders like respiratory diseases and genetic testing. The IVD market in Europe follows the lead and is expected to rise on account of rising cases of cancer, tuberculosis and pneumonia. However, Asia Pacific and China will follow the IVD market trend owing to the rising population and increasing disposable incomes.
Prominent players dominating the global IVD market are Johnson & Johnson (JNJ; New Brunswick, NJ, USA), Siemens Healthcare, BD (Franklin Lakes, NJ, USA), Roche Diagnostics, Abbott Laboratories (Abbot Park, IL, USA), and Beckman Coulter.
Related Links:
Grand View Research
Johnson & Johnson
BD
Abbott Laboratories
Applications of IVD include oncology, cancer, nephrology, cardiology, drug testing, autoimmune diseases, diabetes and infectious diseases, with tests being used by a wide range of customers, including academic institutes, hospitals, and laboratories. Home testing is another application resulting from innovations and advancement in various IVD technologies, further enhancing the increasing role of POC disease diagnostics. This, along with the need for identification of malaria and filiarsis pathogens, are some of the key drivers of IVD market.
Increased consumer awareness of serious health issues such as diabetes, cancer, and sexually transmitted diseases are also rapidly altering the healthcare environment, creating a need for point-of-care (POC) recognition and detection of communicable diseases such as respiratory infections, respiratory syncytial virus (RSV), influenza, and pneumonia. Of particular interest is the tissue IVD market, which is expected to rise owing to the increasing incidents of lung and bronchus cancer, melanoma, and prostate breast cancer diagnosis.
Product-wise, the in IVD market is segmented into instruments, services, data management systems, reagents, and kits that are intended to diagnose, cure, prevent, or treat a particular disease. Different techniques are involved, including molecular diagnostics, blood tests, clinical chemistry, microbiological diagnostic techniques, and flow cytometry. The most commonly used technologies include electrolyte and metabolic panels; lipid and renal profiles; hematology, coagulation, and hemostasis microarrays; and radioimmunoassay and specialty chemicals, among others.
In 2014, North America was the largest regional segment, with about 43% market share owing to established distribution channels, extraordinary diagnostics in cancer screening, and prevalent disorders like respiratory diseases and genetic testing. The IVD market in Europe follows the lead and is expected to rise on account of rising cases of cancer, tuberculosis and pneumonia. However, Asia Pacific and China will follow the IVD market trend owing to the rising population and increasing disposable incomes.
Prominent players dominating the global IVD market are Johnson & Johnson (JNJ; New Brunswick, NJ, USA), Siemens Healthcare, BD (Franklin Lakes, NJ, USA), Roche Diagnostics, Abbott Laboratories (Abbot Park, IL, USA), and Beckman Coulter.
Related Links:
Grand View Research
Johnson & Johnson
BD
Abbott Laboratories
Latest Industry News
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
Channels
Clinical Chemistry
view channel
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read more
Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read moreMolecular Diagnostics
view channel
Blood Test Could Help Detect Gallbladder Cancer Earlier
Gallbladder cancer is one of the deadliest gastrointestinal cancers because it is often diagnosed at an advanced stage when treatment options are limited. Early symptoms are minimal, and current screening... Read more
New Blood Test Score Detects Hidden Alcohol-Related Liver Disease
Fatty liver disease affects nearly one in three adults worldwide and can be driven by metabolic conditions such as obesity and diabetes or by excessive alcohol use. In routine care, it is often difficult... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read morePathology
view channel
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read more
AI-Powered 3D Scanning System Speeds Cancer Screening
Cytology remains a cornerstone of cancer detection, requiring specialists to examine bodily fluids and cells under a microscope. This labor-intensive process involves inspecting up to one million cells... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more







